ImmunityBio Inc. (NASDAQ: IBRX) presented comparative effectiveness data at the 2026 American Urological Association Annual Meeting showing its treatment combination of nogapendekin alfa inbakicept-pmln (NAI, ANKTIVA) plus BCG against two FDA-approved therapies for BCG-unresponsive non-muscle invasive bladder cancer.

The company conducted indirect treatment comparisons using data from its QUILT-3.032 study against published data from competitors' trials. In the comparison with nadofaragene firadenovec-vncg, NAI plus BCG showed a complete response rate of 69.7% versus 53.4%, with a median duration of response of 22.1 months compared to 9.7 months. The treatment combination also demonstrated a 60% reduction in cystectomy risk.

Against TAR-200, NAI plus BCG showed a 12-month complete response rate of 49.2% versus 45.9%, though this difference was not statistically significant. However, patients receiving NAI plus BCG experienced fewer treatment-related adverse events of any grade at 61.7% compared to 83.5% for TAR-200.

"The magnitude and durability of complete response observed with NAI+BCG, combined with a meaningful reduction in the risk of cystectomy, are clinically relevant for patients," said Dr. Brooke Edwards from the Urology Group in Cincinnati.

The analyses were unanchored indirect treatment comparisons, which have inherent limitations as they are not head-to-head clinical trials. Some baseline variables were not mutually reported across trials, limiting the ability to verify full comparability.

ANKTIVA is approved by the FDA as an interleukin-15 receptor agonist used with BCG for treating adult patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ.